Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry ...(ommunications Arena Pharma...),Health
Navigation Links
Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
Date:8/31/2007
ommunications
Arena Pharmaceuticals, Inc.
858.453.7200, ext. 1682
'/>"/>
| SOURCE Arena Pharmaceuticals, Inc. Copyright©2007 PR Newswire. All rights reserved |
Related medicine news :
1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
Breaking Medicine News(10 mins):Health News:FEHBP Open Enrollment Period to be Discussed on Special Rebroadcast of 'Inside Government' 2Health News:Pelosi: Lifting the Ban on Federal Funding for Syringe Exchange is a Victory for Science and for Public Health 2Health News:Most Hospital Patients Don't Know What Meds They're Taking 2Health News:Most Hospital Patients Don't Know What Meds They're Taking 3Health News:Major New Study Finds Soyfoods Safe and Beneficial for Women With Breast Cancer 2
[0] FEHBP Open Enrollment Period to be Discussed on Special Rebroadcast of 'Inside Government'[0] Pelosi: Lifting the Ban on Federal Funding for Syringe Exchange is a Victory for Science and for Public Health[0] Savient To Present at the 28th Annual JP Morgan Healthcare Conference[0] Most Hospital Patients Don't Know What Meds They're Taking[0] Major New Study Finds Soyfoods Safe and Beneficial for Women With Breast Cancer
Breaking Medicine Technology:China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients 13118 1Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients 13118 2Next Generation Hemostatic Dressing Available for Military Emergencies 52198 1Next Generation Hemostatic Dressing Available for Military Emergencies 52198 2Next Generation Hemostatic Dressing Available for Military Emergencies 52198 3BluePrintCleanse to Create a Juice Rush With Free Shipping to State of California 52194 1BluePrintCleanse to Create a Juice Rush With Free Shipping to State of California 52194 2BluePrintCleanse to Create a Juice Rush With Free Shipping to State of California 52194 3
Other Medicine Technology:First of Its Kind Data Show: Immediate Treatment of Early MS,Patients with Betaseron Significantly Delayed Permanent Disability 2First of Its Kind Data Show: Immediate Treatment of Early MS,Patients with Betaseron Significantly Delayed Permanent Disability 3First of Its Kind Data Show: Immediate Treatment of Early MS,Patients with Betaseron Significantly Delayed Permanent Disability 4MabThera Significantly Increases Survival of Lymphoma Patients,Regardless of Chemotherapy Regimen 2MabThera Significantly Increases Survival of Lymphoma Patients,Regardless of Chemotherapy Regimen 3MabThera Significantly Increases Survival of Lymphoma Patients,Regardless of Chemotherapy Regimen 4
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |